Big Changes Are Coming in Hepatitis C

Por Poordad, Fred
Publicado em 2010

Treatment of Hepatitis C Virus Genotype 3 Infection

Por Poordad, Fred
Publicado no Gastroenterol Hepatol (N Y) (2015)

Diagnosis, Treatment, and Monitoring of Patients With Primary Biliary Cholangitis

Por Poordad, Fred
Publicado no Gastroenterol Hepatol (N Y) (2016)

Primary liver cancer surveillance, diagnosis and treatment /

Por Reau, Nancy., Poordad, Fred.
Publicado em 2012

Rapid Virological Response to Peginterferon Alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virological Response and...

Por Poordad, Fred, Landaverde, Carmen
Publicado em 2009

Viral Resistance in Hepatitis B: Prevalence and Management

Por Poordad, Fred, Chee, Grace M.
Publicado em 2010

Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

Por Alkhouri, Naim, Poordad, Fred, Lawitz, Eric
Publicado no Hepatol Commun (2018)

Treatment of patients with hepatitis C virus genotype 3: Where are we now?

Por Landaverde, Carmen, Wells, Jennifer T., Gutierrez, Julio, Poordad, Fred
Publicado no Clin Liver Dis (Hoboken) (2015)

Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient

Por Gutierrez, Julio A., Landaverde, Carmen, Wells, Jennifer T., Poordad, Fred
Publicado no Hepatology (2016)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin

Por Poordad, Fred, Lawitz, Eric, Gutierrez, Julio A., Guerrero, Juan, Speeg, Kermit, Swenson, Eugene S.
Publicado no Clin Case Rep (2017)

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

Por Poordad, Fred, Terrault, Norah A., Alkhouri, Naim, Tian, Wei, Allen, Lee F., Rabinovitz, Mordechai
Publicado no Int J Hepatol (2020)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection

Por Feld, Jordan J., Jacobson, Ira M., Sulkowski, Mark S., Poordad, Fred, Tatsch, Fernando, Pawlotsky, Jean‐Michel
Publicado no Liver Int (2016)

Association of Host Pharmacodynamic Effects with Virologic Response to Peginterferon Alfa-2a/Ribavirin in Chronic Hepatitis C

Por Chung, Raymond T., Poordad, Fred F., Hassanein, Tarek, Zhou, Xiaolei, Lentz, Ellen, Prabhakar, Avinash, Di Bisceglie, Adrian M.
Publicado em 2010

Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Por Loo, Nicole, Lawitz, Eric, Alkhouri, Naim, Wells, Jennifer, Landaverde, Carmen, Coste, Angie, Salcido, Rossalynn, Scott, Michael, Poordad, Fred
Publicado no World J Gastroenterol (2019)

Percutaneous Liver Biopsy after Living Donor Liver Transplantation Resulting in Fulminant Hepatic Failure: The First Reported Case of Hepatic Compartment Syndrome

Por Nissen, Nicholas N., Geller, Stephen A., Klein, Andrew, Colquhoun, Steve, Yamini, David, Tran, Tram T., Weinberg, Benjamin, Winn, Julie, Poordad, Fred
Publicado em 2010

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Por Ferrante, Shannon Allen, Chhatwal, Jagpreet, Brass, Clifford A, El Khoury, Antoine C, Poordad, Fred, Bronowicki, Jean-Pierre, Elbasha, Elamin H
Publicado em 2013

High antiviral activity of NS5A inhibitor ABT‐530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection

Por Poordad, Fred, Landis, Charles S., Asatryan, Armen, Jackson, Daniel F., Ng, Teresa I., Fu, Bo, Lin, Chih‐Wei, Yao, Betty, Kort, Jens
Publicado no Liver Int (2016)

Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort

Por Khoudari, George, Singh, Amandeep, Noureddin, Mazen, Fritze, Danielle, Lopez, Rocio, Asaad, Imad, Lawitz, Eric, Poordad, Fred, Kowdley, Kris V, Alkhouri, Naim
Publicado no World J Hepatol (2019)

Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient

Por Nissen, Nicholas N, Menon, Vijay, Bresee, Catherine, Tran, Tram T, Annamalai, Alagappan, Poordad, Fred, Fair, Jeffrey H, Klein, Andrew S, Boland, Brendan, Colquhoun, Steven D
Publicado em 2011

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

Por Lawitz, Eric, Poordad, Fred, Brainard, Diana M, Hyland, Robert H, An, Di, Dvory-Sobol, Hadas, Symonds, William T, McHutchison, John G, Membreno, Fernando E
Publicado no Hepatology (2015)